What are the main contraindications to Sotatercept-Winrevair?

Sotatercept-Winrevair is a recombinant fusion protein targeting the BMP/TGF-β signaling pathway. It is mainly used to improve pulmonary arterial hypertension (PAH) related diseases. Its unique mechanism brings significant therapeutic advantages, but at the same time there are strict contraindications for specific patient groups. First, for patients with a known allergy to Soltercept itself or to the drug components, the use of Soltercept may cause severe allergic reactions or even life-threatening reactions, and is therefore classified as an absolute contraindication. This type of allergic reaction may include rash, difficulty breathing and systemic immune reaction, so patients need to be asked about their past allergic history in detail before taking the drug.

Second, soltercept may affect hemodynamic status and should be used with caution or avoided in patients with severe heart failure, severe hypertension, or severe aortic stenosis. Drug interventionBMP/TGF-β signaling pathway may have potential effects on the cardiovascular system and increase the risk of cardiac events. These patients need to undergo a comprehensive cardiac assessment and risk management before using sotercept, and their blood pressure, heart rate and cardiac function indicators should be closely monitored during treatment.

Pregnant and lactating women are also important contraindications for Soltrecept. Due to the current lack of adequate safety data, the drug may pose unknown risks to the fetus or infant and is not recommended for use during pregnancy or lactation. For patients with severely impaired liver function or other severe organ dysfunction, the metabolism and clearance of soltercept may be affected, thereby changing the plasma concentration and safety, and should also be used with caution.

In addition, be aware of the potential for elevated hemoglobin and increased risk of thrombosis when used with other erythropoiesis-stimulating drugs. Therefore, patients who are receiving other drugs that affect erythropoiesis need to use sotercept under the guidance of a physician to avoid potential adverse events. Clinically, the evaluation of contraindications not only includes basic diseases and organ functions, but also should be combined with the patient's previous medication history and physiological status to ensure the safety of medication.

Reference materials:https://www.drugs.com/mtm/sotatercept.html